AR089771A1 - Derivados de bencil sulfonamida utiles como inhibidores de mogat-2 - Google Patents

Derivados de bencil sulfonamida utiles como inhibidores de mogat-2

Info

Publication number
AR089771A1
AR089771A1 ARP130100180A ARP130100180A AR089771A1 AR 089771 A1 AR089771 A1 AR 089771A1 AR P130100180 A ARP130100180 A AR P130100180A AR P130100180 A ARP130100180 A AR P130100180A AR 089771 A1 AR089771 A1 AR 089771A1
Authority
AR
Argentina
Prior art keywords
mogat
bencil
inhibitors
derivatives
useful
Prior art date
Application number
ARP130100180A
Other languages
English (en)
Spanish (es)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47148691&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR089771(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AR089771A1 publication Critical patent/AR089771A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/03Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C311/05Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • C07D213/63One oxygen atom
    • C07D213/64One oxygen atom attached in position 2 or 6
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • C07D213/63One oxygen atom
    • C07D213/65One oxygen atom attached in position 3 or 5

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
ARP130100180A 2012-01-31 2013-01-21 Derivados de bencil sulfonamida utiles como inhibidores de mogat-2 AR089771A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261592717P 2012-01-31 2012-01-31
EP12382432 2012-11-06

Publications (1)

Publication Number Publication Date
AR089771A1 true AR089771A1 (es) 2014-09-17

Family

ID=47148691

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130100180A AR089771A1 (es) 2012-01-31 2013-01-21 Derivados de bencil sulfonamida utiles como inhibidores de mogat-2

Country Status (27)

Country Link
US (1) US8575352B2 (enExample)
EP (1) EP2809651B1 (enExample)
JP (1) JP2015511232A (enExample)
KR (1) KR20140106750A (enExample)
CN (1) CN104066719B (enExample)
AP (1) AP2014007794A0 (enExample)
AR (1) AR089771A1 (enExample)
AU (1) AU2013215468A1 (enExample)
BR (1) BR112014018636A8 (enExample)
CA (1) CA2859995A1 (enExample)
CL (1) CL2014001861A1 (enExample)
CO (1) CO7010839A2 (enExample)
CR (1) CR20140322A (enExample)
DO (1) DOP2014000178A (enExample)
EA (1) EA201491276A1 (enExample)
ES (1) ES2590929T3 (enExample)
GT (1) GT201400167A (enExample)
HK (1) HK1199025A1 (enExample)
IL (1) IL233712A0 (enExample)
MA (1) MA35886B1 (enExample)
MX (1) MX2014008599A (enExample)
PE (1) PE20141679A1 (enExample)
PH (1) PH12014501711A1 (enExample)
SG (1) SG11201404106QA (enExample)
TW (1) TW201343629A (enExample)
WO (1) WO2013116075A1 (enExample)
ZA (1) ZA201404836B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013112323A1 (en) 2012-01-23 2013-08-01 Eli Lilly And Company Phenyl methanesulfonamide derivatives useful as mgat - 2 inhibitors
JP5852269B2 (ja) 2012-01-31 2016-02-03 イーライ リリー アンド カンパニー Mogat−2阻害剤として有用な新規モルホリニル誘導体
EA201590696A1 (ru) 2012-11-06 2015-08-31 Эли Лилли Энд Компани Новые бензилсульфонамидные соединения, подходящие в качестве ингибиторов mogat-2
CA2986611C (en) 2015-06-15 2023-10-03 Nmd Pharma Aps Compounds for use in treating neuromuscular disorders
TWI782056B (zh) 2017-07-14 2022-11-01 日商鹽野義製藥股份有限公司 具有mgat2抑制活性的縮合環衍生物
US10385028B2 (en) 2017-12-14 2019-08-20 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders
US11730714B2 (en) 2017-12-14 2023-08-22 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders
US12440477B2 (en) 2017-12-14 2025-10-14 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders
US11147788B2 (en) 2017-12-14 2021-10-19 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders
US11591284B2 (en) 2017-12-14 2023-02-28 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders
JP7608166B2 (ja) 2019-01-11 2025-01-06 塩野義製薬株式会社 Mgat2阻害活性を有するジヒドロピラゾロピラジノン誘導体

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1659113A1 (en) * 2004-11-08 2006-05-24 Evotec AG Inhibitors of 11beta-hydroxy steroid dehydrogenase type 1 (11beta-HSD1)
EP1655283A1 (en) * 2004-11-08 2006-05-10 Evotec OAI AG 11beta-HSD1 Inhibitors
EA200701035A1 (ru) * 2004-11-10 2007-10-26 Пфайзер Инк. Замещенные n-сульфониламинобензил-2-феноксиацетамидные соединения
CN101087771A (zh) * 2004-11-10 2007-12-12 辉瑞大药厂 经取代n-磺酰基氨基苄基-2-苯氧基乙酰胺化合物
AU2007297285A1 (en) * 2006-09-08 2008-03-20 Pfizer Products Inc. Diaryl ether derivatives and uses thereof
EP2078719A4 (en) * 2006-09-28 2009-11-11 Dainippon Sumitomo Pharma Co COMPOUND WITH BICYCLIC PYRIMIDINE STRUCTURE AND THE COMPOUND CONTAINING PHARMACEUTICAL COMPOSITION
CN101583593A (zh) * 2006-11-13 2009-11-18 辉瑞产品公司 二芳基、二吡啶基和芳基-吡啶基衍生物及其用途
AU2008345225A1 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
CA2751244A1 (en) * 2009-02-23 2010-08-26 Msd K.K. Pyrimidin-4(3h)-one derivatives
WO2013112323A1 (en) 2012-01-23 2013-08-01 Eli Lilly And Company Phenyl methanesulfonamide derivatives useful as mgat - 2 inhibitors
JP5852269B2 (ja) 2012-01-31 2016-02-03 イーライ リリー アンド カンパニー Mogat−2阻害剤として有用な新規モルホリニル誘導体

Also Published As

Publication number Publication date
EA201491276A1 (ru) 2014-10-30
CN104066719A (zh) 2014-09-24
BR112014018636A8 (pt) 2017-07-11
AP2014007794A0 (en) 2014-07-31
US20130197039A1 (en) 2013-08-01
JP2015511232A (ja) 2015-04-16
CN104066719B (zh) 2016-08-24
PE20141679A1 (es) 2014-11-08
CA2859995A1 (en) 2013-08-08
AU2013215468A1 (en) 2014-07-10
CO7010839A2 (es) 2014-07-31
IL233712A0 (en) 2014-09-30
TW201343629A (zh) 2013-11-01
EP2809651B1 (en) 2016-06-29
WO2013116075A1 (en) 2013-08-08
BR112014018636A2 (enExample) 2017-06-20
HK1199025A1 (en) 2015-06-19
US8575352B2 (en) 2013-11-05
ZA201404836B (en) 2017-08-30
ES2590929T3 (es) 2016-11-24
DOP2014000178A (es) 2014-08-31
PH12014501711A1 (en) 2014-10-13
CL2014001861A1 (es) 2014-11-07
KR20140106750A (ko) 2014-09-03
SG11201404106QA (en) 2014-08-28
GT201400167A (es) 2015-05-28
MA35886B1 (fr) 2014-12-01
EP2809651A1 (en) 2014-12-10
CR20140322A (es) 2014-08-25
MX2014008599A (es) 2014-08-22

Similar Documents

Publication Publication Date Title
AR089771A1 (es) Derivados de bencil sulfonamida utiles como inhibidores de mogat-2
AR102977A1 (es) Inhibidores de erk
AR091519A1 (es) Inhibidores pirrolopirazona de tanquirasa
AR101815A1 (es) Compuestos y composiciones como inhibidores de quinasa
MX373196B (es) Inhibidores de histona desacetilasa novedosos.
AR093759A1 (es) Dihidropiridona p1 como inhibidores del factor xia
EA201591455A1 (ru) Производные бензимидазолона в качестве ингибиторов бромодомена
AR101558A1 (es) Difluoropirrolidinas como moduladores del receptor de orexina
AR094314A1 (es) Inhibidores de fosfatidilinositol 3-cinasa
CR20120417A (es) Inhibidores de virus flaviviridae
EA201401081A1 (ru) Циклические амиды в качестве ингибиторов метар-2
MX342212B (es) Inhibidores de neprilisina.
CR20150018A (es) Inhibidores macrocíclicos de virus flaviviridae
AR099177A1 (es) Determinadas (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1
CU24385B1 (es) Compuestos éteres de arilo útiles para tratar cancer de célula renal
AR090474A1 (es) Compuestos de tetrahidropirrolotiazina
AR094959A1 (es) Compuestos de imidazo piridina
AR089550A1 (es) Compuestos quimicos
AR091431A1 (es) Compuestos de acido dimetil-benzoico
AR097866A1 (es) Derivados de 4-azaindol
EA201300442A1 (ru) ПИРРОЛИДИНОНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ MetAP-2
AR107428A1 (es) COMPUESTOS DE ISOXAZOL DE ÁCIDO HIDROXÁMICO COMO INHIBIDORES DE LpxC
CR20160030A (es) Nuevos compuestos isoindolina o isoquinolina, un proceso para su preparación y composiciones farmacéuticas que los contienen
AR091770A1 (es) Indolcarbonitrilos moduladores selectivos de receptores androgenicos
AR091773A1 (es) Inhibidores de la histona desacetilasa y composiciones y sus metodos de uso

Legal Events

Date Code Title Description
FB Suspension of granting procedure